SCHEMBL115514

SCHEMBL115514

O=Cc1ccncc1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29640748 1.00
SCHEMBL29957409 0.82
SCHEMBL878387 0.82
SCHEMBL29955436 0.78 KMT2A (0.46)
SCHEMBL2600757 0.78 KMT2A (0.46)
SCHEMBL23457261 0.77
SCHEMBL12530511 0.77
SCHEMBL5321132 0.77
SCHEMBL21182060 0.77
SCHEMBL27243807 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121577669-A Amino acid based on difunctional derivatization reagent19Fsabre hyperpolarization method 厦门大学 2026-02-27 CN claimed
CN-119381594-A Aqueous zinc ion battery electrolyte additive capable of forming organic/inorganic hybridization SEI film and electrolyte 淮阴师范学院 2025-01-28 CN claimed
CN-121577669-A Amino acid based on difunctional derivatization reagent19Fsabre hyperpolarization method 厦门大学 2026-02-27 CN disclosed
EP-4126835-B1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 EP disclosed
US-12516038-B2 Inhibitors of antigen presentation by HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-01-06 US disclosed
EP-4638432-A1 AZOLE COMPOUNDS FOR CONTROLLING AND COMBATING INVERTEBRATE PESTS FMC Corporation (US) 2025-10-29 EP disclosed
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 US disclosed
US-20250171461-A1 STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC (US) 2025-05-29 US disclosed
CN-116283701-B Compounds having the structure 4- (substituted aminomethyl) -5-neopentyl-N-substituted pyrrolidine-2-carboxamide 中国科学院上海药物研究所 2025-04-22 CN disclosed
US-20250115590-A1 MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF FORESEE PHARMACEUTICALS USA, INC. 2025-04-10 US disclosed
EP-0882714-A1 SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME SS Pharmaceutical Co., Ltd. (JP) 1998-12-09 EP disclosed
US-5817693-A Endothelin receptor antagonists SMITHKLINE BEECHAM CORPORATION 1998-10-06 US disclosed
US-5719183-A HYPOTENSIVE AGENTS; KIDNEY DISEASES; ANTIISCHEMIC AGENTS SMITHKLINE BEECHAM CORPORATION (US) 1998-02-17 US disclosed
US-5719182-A TREATING HYPERTENSION, RENAL FAILURE, CEREBROVASCULAR DISEASE SMITHKLINE BEECHAM CORPORATION (US) 1998-02-17 US disclosed
US-5716984-A INDANE AND INDENE DERIVATIVES; TREATMENT OF CARDIOVASCULAR DISORDERS, KIDNEY DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 1998-02-10 US disclosed
US-5563150-A Pyrrolo-pyridine derivatives MERCK, SHARP & DOHME LTD. (GB) 1996-10-08 US disclosed
EP-0699069-A4 1996-04-03 EP disclosed
EP-0699069-A1 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-03-06 EP disclosed
WO-1994025013-A1 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-11-10 WO disclosed